The first effective coronavirus vaccine can prevent more than 90% of people from getting Covid-19, a preliminary analysis has shown. The developers – Pfizer and BioNTech – described it as a “great day for science and humanity”. The analysis evaluated 94 confirmed cases of COVID-19 in trial participants. Daniel Davis,… Read More
Pfizer and BioNTech have announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase… Read More
Analysis from virtual clinical development specialist Phesi shows the enrolment and effectiveness of two current COVID-19 vaccine trials conducted by global pharmaceutical development companies. On the surface, both trials appear to be on track to complete enrolment, however, looking deeper, there is a significant difference in the Site Effectiveness Index… Read More
Moderna has announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19. “We appreciate the confidence of the Ministry of Health of Qatar in our mRNA vaccine platform and the collaboration we have had to date,” said Stéphane Bancel, Moderna’s Chief… Read More
The AstraZeneca Oxford COVID-19 vaccine (ChAdOx1 nCoV-19 and also known as AZD1222) has been shown to work as planned. A team at Bristol University has used recently developed techniques to further validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford team. This novel analysis… Read More
The Food and Drug Administration (FDA) has today authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford coronavirus vaccine in the USA following the trials restarting in the UK, Brazil, South Africa and Japan. On 6 September, a standard review process triggered a voluntary pause to vaccination across… Read More
hVIVO, has signed a contract with the UK government to develop a COVID-19 (SARS-CoV-2) human challenge study model. The model development involves the manufacture of the challenge virus and the first-in-human characterisation study for this virus. The contract starts immediately and could be worth approximately £10 million to hVIVO –… Read More
Robin Vacha, Senior Vice President, Products at Brooks Life Sciences and David Lewandowski, Global Business Development Manager, Cryo Division at Brooks Life Sciences examine the role of unbroken cold chain in research and development As COVID-19 vaccine research continues to grow at an unparalleled pace, so does the need for… Read More
Almost seven in 10 Americans would be interested in receiving a COVID-19 vaccine, a study finds. But researchers say there are concerning gaps in interest, particularly among Black Americans, who suffer disproportionately from the virus. Researchers from The Ohio State University surveyed more than 2,000 Americans, asking them about their… Read More
What a time to be involved in drug discovery. While COVID-19 has of course created unprecedented conditions on a global scale, it has also highlighted the extent to which this sector offers depth of knowledge, skill and innovation. It is a pleasure to learn more about the market – both… Read More
By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to… Read More
THE COVID-19 RACE how mouse models will help researchers cross the finish line By Dr Megan MacBride The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission… Read More
By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used… Read More
By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Biopharmaceutical companies must develop manufacturing solutions that will enable them to… Read More
Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 - Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Read More
The COVID-19 antiviral race: we're all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically… Read More